Key Takeaways
- Challenging quarter, price-led degrowth: Revenue fell on both volume decline and sharp price erosion, with domestic business hit by delayed monsoon and excess channel inventory, while international faced severe generic pricing pressure.
- Margins improved despite revenue drop: EBITDA margin expanded through timely pricing actions, better product mix, and control on fixed costs, aided by liquidation of high-cost inventory in prior periods.
- Seeds business a bright spot: The Diggaz cotton hybrid saw volume jump to 4 lakh packets from 1.5 lakh packets YoY, and overall seed placement was satisfactory despite marginally lower revenue.
- New manufacturing engines loading: Trial production began at the Dahej MPP plant, three new contract manufacturing deals were signed, and PEKK exports for aerospace resumed after a two-year gap.
- What to watch next quarter: Whether Kharif sowing recovery translates into liquidation of channel inventory, the trajectory of Acephate pricing in Brazil, and revenue commencement from the new MPP plant.
Revenue Degrowth: Price and Volume Pressure
- Domestic crop care: Volumes were largely flattish, so the degrowth was led by price; delayed monsoon and excess channel inventory restricted placement during the quarter.
- International crop care: A large part of the degrowth came from volumes, with sharp price erosion across major generic active ingredients compounding the impact.
- Channel inventory overhang: Higher carryover inventory from the previous year, driven by low pest infestation in the Rabi season, kept trade cautious and purchasing closer to consumption.
- Key product pricing: Acephate and Hexaconazole prices continue to trend lower; Pendimethalin prices have been somewhat stable. DMPAT, a key starting material for Acephate, has fallen over 40% from its peak, dragging product prices down sharply.
- Q2 early signal: Excessive rainfall in the northwest means consumption of many chemicals will have to wait; clearer liquidation trends will emerge only as Q2 progresses.
Sanjiv Lal: "The prices have been coming down quite sharply and practically there's been new pricing which is being offered on a day to day basis. So, the issue is that, even the customer is seeing this declining price trend and for our products also, they are demanding lower pricing."
Margin Resilience
- Gross margin expansion: Driven by product mix (domestic versus international) and within products sold; selling off high-price inventory from prior periods helped, and at the portfolio level margins were similar or slightly better.
- Prudent procurement: The company reduced procurement quantities to limit impact if prices fall further, and took more frequent pricing calls, downwards when necessary and upwards when necessary.
- Seeds margin tailwind: Q1 is the seeds business where margins are relatively better, and the season has gone off well, contributing positively to the overall margin profile.
- No one-offs or write-backs: Management confirmed there were no one-offs in domestic business performance and no material write-offs or reversals in the quarter.
Subhra Gourisaria: "You should remember that Q1 is a seeds business where the margins are relatively better. So if the domestic business does well, which makes better gross margin for us, the margin should continue to improve. But it's too early or too premature to say, because it's dependent on various factors."
Seeds: Diggaz Breakout
- Diggaz volume surge: The North cotton hybrid sold 4 lakh packets in Q1 FY24 versus 1.5 lakh packets in Q1 FY23, with management believing all have been sold out.
- Pricing strategy: The product is priced at a similar level to existing products, with no value extraction through a premium, which is driving adoption.
- Acreage expansion underway: Work is currently underway to secure acreages for expanding availability for the next season, with management hopeful of growing the product further.
- Overall seeds placement: Placement efforts were quite satisfactory despite revenue being marginally lower over the previous year.
Sanjiv Lal: "Last year also we had a very positive response, although the volumes which we sold were limited by what we had, which was about 1.5 lakh packets and we had scaled up to about 4 lakh packets, which practically we believe have all got sold out."
New Manufacturing Capacity
- Dahej MPP trial production: Trial production for Difenoconazole at the multipurpose plant started in June; revenue will begin accruing from Q2 onwards.
- MPP product roadmap: Difenoconazole trial ongoing; one contract manufacturing molecule expected towards end of Q3; another intermediate also expected towards Q3; Q2 will largely be Difenoconazole.
- MPP capacity utilisation: Management expects about 60% capacity utilisation this year, with a much better number next year.
- PEKK revival: Exports of PEKK for aerospace have commenced, with dispatches starting from Q4 of FY23; volumes are expected to steadily pick up over the next couple of years to pre-pandemic levels, though current scale is not at peak capacity.
- Contract manufacturing wins: Three new contract manufacturing opportunities were signed and dispatch of one intermediate commenced during the quarter.
- Pendimethalin EU access: Secured technical equivalence in the EU, opening a new market; raw material supplies have also been secured.
International Markets and Product Dynamics
- Acephate pressure: Very sharp price reduction driven by DMPAT cost decline and additional capacity from newer players establishing themselves with intermediates; exported largely to Brazil, where the season picks up in Q2.
- Pendimethalin stability: Demand largely stable with some price correction; outlook remains positive due to new EU market access.
- Hexaconazole revival: Some revival in consumption and off-take seen in Southeast Asia.
- Metribuzin outlook: More or less flat with maybe a slight uptake in volume expected going forward; it is a smaller-volume product.
- Brazil season watch: Season in Brazil picks up in Q2; if it goes well, there could be significant demand returning, though management remains cautious on Acephate specifically.
- Volume recovery key: Pricing growth is unlikely in the near term; volume recovery will be the key driver for overall growth, with international markets cautious due to higher inventories.
Strategic Initiatives and Capex
- Network expansion: Work on widening distribution reach started a couple of quarters back, helping increase reach and width of distribution.
- Digitisation: Deployed SAP integrated business planning solution to enable more agile and precise decision-making while digitising many processes.
- New product launches: Launched new products this season in crop nutrition and seeds; the company will participate in the Chlorantraniliprole segment with two formulations.
- China dependency reduction: Efforts towards lowering dependency on China for raw materials will contribute meaningfully in the coming years.
- Capex plan: Approximately ₹150 crore for the year, including spend on a new R&D facility and de-bottlenecking for one or two products.
- Cash flow focus: Cash flows have improved with specific focus on inventory reduction and collections; absolute EBITDA and cash flow are key priorities.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| MPP revenue commencement | Revenue from Difenoconazole trial production to start accruing | Q2 FY24 |
| MPP capacity utilisation | Approximately 60% utilisation expected | FY24 |
| Capex | Approximately ₹150 crore, including new R&D facility and de-bottlenecking | FY24 |
| Contract manufacturing molecule at MPP | One molecule expected towards end of Q3 | Q3 FY24 |
| Second-half recovery | Situation expected to ease | Second half of fiscal |
| PEKK volume recovery | Steady pick-up to pre-pandemic levels | Over next couple of years |
| China dependency reduction | Efforts to contribute meaningfully | Coming years |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Revenue | ₹782 cr, -9% YoY vs ₹863 cr in Q1 FY23 |
| EBITDA | ₹109 cr, vs ₹113 cr in Q1 FY23 |
| EBITDA margin | 14%, vs 13% in Q1 FY23 |
| Profit after tax | ₹63 cr, vs ₹67 cr in Q1 FY23 |
| PAT margin | 8.1%, vs 7.8% in Q1 FY23 |
| Crop care revenue growth | -13% YoY |
| Seeds revenue | ₹262 cr, broadly flat, -2% YoY |
| Domestic crop care volume growth | Largely flattish YoY |
| International crop care price decline | Sub-10% YoY |
| Diggaz cotton hybrid packets sold | 4 lakh packets, vs 1.5 lakh packets in Q1 FY23 |
| Domestic crop care distribution network | 4,700 distributors, retail footprint of 61,000 as of end June |
| Seeds distribution network | 2,750 distributors, retail footprint of 47,000 as of end June |
| Innovation Turnover Index | ~13% in FY23, target of ~15% |
| Capex guidance for FY24 | ₹150 cr |
| Working capital loan repaid during quarter | ₹25 cr |